The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Essential Thrombocythemia (ET): Diagnosis and Risk-Adapted Therapy

Persistent thrombocytosis, thrombotic and bleeding risks and modern management

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Essential Thrombocythemia (ET): Diagnosis and Risk-Adapted Therapy?

Essential thrombocythemia is defined by persistent platelet count above 450 x 10^9/L with characteristic megakaryocyte hyperplasia and absence of other myeloproliferative or reactive causes.

Driver mutations include JAK2 V617F (about 60 percent), CALR (20 to 25 percent) and MPL (3 to 5 percent), with triple-negative cases retaining clinical significance.

Diagnosis requires bone marrow biopsy, mutation panel, exclusion of reactive thrombocytosis and other myeloid neoplasms.

Risk stratification considers age, prior thrombosis, JAK2 mutation status and cardiovascular risk factors (IPSET-thrombosis).

Long-term complications include arterial and venous thromboses, hemorrhage, microvascular symptoms and progression to myelofibrosis or acute leukemia.

Symptoms

Headache, dizziness, blurred vision, paresthesia and erythromelalgia from microvascular dysfunction.
Atypical thrombosis sites including splanchnic veins and cerebral sinuses.
Bleeding tendencies usually with extreme thrombocytosis above 1500 x 10^9/L due to acquired von Willebrand disease.
Splenomegaly is mild or absent in most patients.
Constitutional symptoms (fatigue, night sweats, pruritus) are less prominent than in polycythemia vera or myelofibrosis.

Risk Factors

Older age and female predominance.
Family history of myeloproliferative neoplasm.
JAK2 V617F mutation associates with higher thrombotic risk.
Cardiovascular risk factors (smoking, hypertension, diabetes, hyperlipidemia).
Prior thromboembolic events increase recurrence risk.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Symptoms suggestive of stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis or pulmonary embolism require emergency evaluation.
  • Severe headache, visual disturbance or sudden neurological deficit warrants urgent assessment.
  • Unusual bleeding, mucosal bleeding or major hemorrhage requires hematology review.
  • Persistent constitutional symptoms, weight loss or rapid spleen enlargement may indicate transformation.
  • Routine follow-up monitors platelet count, symptom burden, treatment side effects and need for therapy adjustment.

Treatment Methods

01
Low-risk patients receive low-dose aspirin only, balancing thrombotic and bleeding risk.
02
Intermediate and high-risk patients require cytoreductive therapy with hydroxyurea as first-line agent.
03
Anagrelide is an alternative cytoreductive agent particularly when leukocytes are normal.
04
Pegylated interferon alfa-2a is preferred in younger patients, women of reproductive age or pregnancy.
05
Ruxolitinib and busulfan are reserved for refractory or intolerant cases; control of cardiovascular risk factors, vaccination and monitoring for transformation are essential.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.